Trulicity Cardiovascular Impact Long-Term: What the Evidence Actually Shows

Why Cardiovascular Outcomes Matter in Type 2 Diabetes

Adults with type 2 diabetes (T2D) face a two- to four-fold higher risk of cardiovascular death compared with those without the condition. That elevated risk persists even after adjusting for hypertension, dyslipidemia, and smoking.

The FDA began requiring cardiovascular outcomes trials (CVOTs) for all new diabetes drugs after the 2007 rosiglitazone controversy. Those trials changed prescribing fundamentally. Drugs that had been chosen purely on glycemic grounds now had to prove they did not harm the heart, and several went further and proved they helped it.

Dulaglutide's CVOT, REWIND, was designed from the start to test superiority rather than simply non-inferiority. That design choice, combined with a follow-up period nearly twice as long as most CVOTs, gives its findings an unusually strong clinical signal.

The Broader GLP-1 Cardiovascular Picture

GLP-1 receptor agonists reduce cardiovascular events through several proposed mechanisms. They lower fasting and postprandial glucose, reduce systolic blood pressure by roughly 2 to 4 mmHg, reduce body weight, and may exert direct anti-inflammatory and anti-atherosclerotic effects on the vessel wall independent of glucose control. Animal models show GLP-1 receptors expressed on cardiomyocytes and in coronary vasculature, but the degree to which those receptors drive the clinical CV benefit in humans remains debated.

Not every GLP-1 agent has shown the same cardiovascular signal. Exenatide twice daily (EXSCEL) and lixisenatide (ELIXA) showed neutral results. Liraglutide (LEADER, N=9,340), semaglutide 0.5/1 mg (SUSTAIN-6, N=3,297), and dulaglutide (REWIND, N=9,901) showed statistically significant MACE reductions. The molecular and structural differences among these agents may partly explain the divergence, though trial design differences also play a role. [1]

What Counts as a MACE Endpoint

REWIND used a three-component MACE endpoint: non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes. A patient had to experience at least one of these adjudicated events to count as an endpoint. The 12% relative risk reduction seen with dulaglutide translates to a hazard ratio of 0.88 (95% CI 0.79 to 0.99, P=0.026). [2]

The REWIND Trial: Design and Key Findings

REWIND enrolled 9,901 adults with T2D at 371 sites across 24 countries. [2] Participants had to have either a prior cardiovascular event or cardiovascular risk factors, but the eligibility criteria were deliberately broad.

Patient Population and Baseline Characteristics

The median age at enrollment was 66.2 years, and 46% of participants were women, a notably higher female representation than in most CVOTs. HbA1c at baseline averaged 7.3%, lower than the baseline HbA1c in LEADER (8.7%) or SUSTAIN-6 (8.7%). Only 31.5% of REWIND participants had a history of cardiovascular disease at baseline; the other 68.5% qualified on the basis of risk factors alone (age 55 or older with at least two cardiovascular risk factors, or age 60 or older with at least one). [2]

That distinction matters. Most earlier CVOTs enrolled populations enriched for established atherosclerotic cardiovascular disease (ASCVD). REWIND's predominantly primary-prevention population more closely resembles the everyday T2D patient seen in a primary care office.

Primary Endpoint Results

Over a median 5.4 years of follow-up, 594 patients in the dulaglutide arm (12.0%) experienced a MACE event versus 663 patients in the placebo arm (13.4%). The resulting HR of 0.88 reached statistical significance (P=0.026). [2]

The number needed to treat (NNT) to prevent one MACE event over 5.4 years was approximately 71. That compares favorably with many established cardiovascular interventions in similar populations.

Component-by-Component Breakdown

When REWIND's authors analyzed the three MACE components individually, non-fatal stroke drove the most prominent signal:

• Non-fatal stroke: HR 0.76 (95% CI 0.61 to 0.95), a 24% relative reduction. [2]
• Non-fatal myocardial infarction: HR 0.96 (95% CI 0.79 to 1.16), not statistically significant. [2]
• Cardiovascular death: HR 0.91 (95% CI 0.78 to 1.07), not statistically significant. [2]

The stroke reduction is the most consistent finding across REWIND's subgroup analyses and is not fully explained by the modest blood-pressure lowering dulaglutide achieves. Researchers have speculated that reductions in atrial fibrillation burden, platelet aggregation, or endothelial inflammation may contribute, but those hypotheses require prospective testing.

Subgroup Analyses: Who Benefits?

A pre-specified subgroup analysis showed that the cardiovascular benefit did not significantly differ between patients with prior CV disease and those without (interaction P=0.97). [2] That finding supports use of dulaglutide not only for secondary prevention but also for primary prevention in high-risk T2D patients, the population that makes up the large majority of people starting a GLP-1 agent today.

Benefit was consistent across sex, age group, baseline HbA1c, eGFR above 15 mL/min/1.73m2, and presence or absence of metformin use.

How REWIND Compares with Other GLP-1 CVOTs

The table below places REWIND in context with the two other positive GLP-1 CVOTs.

| Trial | Drug | N | Median follow-up | MACE HR (95% CI) | Prior CVD | |---|---|---|---|---|---| | LEADER | Liraglutide 1.8 mg | 9,340 | 3.8 years | 0.87 (0.78 to 0.97) | 81% | | SUSTAIN-6 | Semaglutide 0.5/1 mg | 3,297 | 2.1 years | 0.74 (0.58 to 0.95) | 83% | | REWIND | Dulaglutide 1.5 mg | 9,901 | 5.4 years | 0.88 (0.79 to 0.99) | 32% |

Sources: [2], [3], [4]

The SUSTAIN-6 result looks numerically larger (HR 0.74), but that trial was shorter, smaller, and enrolled a higher-risk population. REWIND's 5.4-year follow-up provides a longer time horizon for a sustained effect. LEADER's result (HR 0.87) is nearly identical numerically to REWIND's and was also powered in a predominantly secondary-prevention population.

The practical takeaway: dulaglutide, liraglutide, and once-weekly subcutaneous semaglutide all carry guideline-supported cardiovascular benefit. The choice among them depends on patient-specific factors including cost, pen-device preference, renal function, and whether weight loss is a co-primary goal.

ADA and ACC Guideline Positioning

The 2024 American Diabetes Association Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." [5] Dulaglutide is listed explicitly as an agent with Level A evidence for cardiovascular benefit.

The American College of Cardiology's 2023 Expert Consensus Decision Pathway similarly lists dulaglutide alongside liraglutide and semaglutide as preferred agents when cardiovascular risk reduction is a therapeutic priority, independent of additional HbA1c lowering needed. [6]

Renal and Secondary Outcomes in REWIND

Cardiovascular and renal disease are closely linked in T2D. REWIND's pre-specified secondary analysis of renal outcomes showed that dulaglutide reduced a composite renal endpoint (new macroalbuminuria, sustained 40% decline in eGFR, or chronic renal replacement therapy) by 15% (HR 0.85, 95% CI 0.77 to 0.93). [7]

What the Renal Data Add

The renal benefit, published separately in The Lancet Diabetes and Endocrinology, was driven primarily by a reduction in new-onset macroalbuminuria rather than hard renal endpoints such as dialysis initiation. The clinical significance of that distinction is still being evaluated, but albuminuria reduction is an accepted surrogate for slowed nephropathy progression.

Glycemic Effects Over 5 Years

HbA1c declined by approximately 0.61 percentage points more with dulaglutide than with placebo over the first year, with the difference narrowing modestly over 5.4 years as the placebo group's background therapy was adjusted by investigators. [2] The cardiovascular benefit seen in REWIND therefore cannot be attributed entirely to glucose lowering; it appears to extend beyond what HbA1c reduction alone would predict.

Body weight declined by roughly 1.4 kg more in the dulaglutide group. That is smaller than the weight loss seen in semaglutide 2.4 mg (Ozempic/Wegovy) trials, because REWIND used the 1.5 mg diabetes dose rather than a higher obesity dose.

Long-Term Safety: What Five-Plus Years of Data Reveal

A 5.4-year median follow-up is longer than most drug safety datasets accumulated before post-marketing use. The REWIND safety data show a consistent and largely predictable profile. [2]

Gastrointestinal Adverse Events

Nausea occurred in 20.3% of dulaglutide participants versus 12.7% on placebo, diarrhea in 12.5% vs. 7.5%, and vomiting in 7.9% vs. 4.1%. Most events were mild to moderate and occurred during the first 4 to 8 weeks of treatment. The 5.4-year exposure period confirms that GI tolerability does not substantially worsen with prolonged use.

Pancreatitis

Pancreatitis was numerically similar between groups (0.3% dulaglutide vs. 0.3% placebo), providing reassurance that the early-signal concern from preclinical GLP-1 studies has not materialized into a clinical pattern in long-term follow-up.

Cancer Signals

Pancreatic cancer occurred in 13 dulaglutide patients and 8 placebo patients, a difference that did not reach statistical significance and that the REWIND authors attributed to chance given the small absolute numbers. No thyroid C-cell tumor signal comparable to the rodent finding with liraglutide has been reported for dulaglutide in human data to date.

Heart Rate

Resting heart rate increased by approximately 2 to 3 beats per minute with dulaglutide, consistent with the GLP-1 class effect. This modest increase has not translated into increased arrhythmia or sudden cardiac death in REWIND or other long-term GLP-1 trials.

Practical Prescribing Considerations for High-Cardiovascular-Risk Patients

Dulaglutide 1.5 mg once weekly is the dose studied in REWIND and the dose that carries the FDA-approved cardiovascular risk reduction indication. Prescribers who start at 0.75 mg to improve GI tolerability should up-titrate to 1.5 mg within 4 weeks unless clearly contraindicated. [8]

Renal Dosing

Dulaglutide does not require dose adjustment for renal impairment and is not renally cleared. The FDA label permits use down to an eGFR of 15 mL/min/1.73m2, which gives it an advantage over metformin (contraindicated below eGFR 30) and some SGLT-2 inhibitors that lose glycemic efficacy at lower eGFR values.

Combination with SGLT-2 Inhibitors

Many high-cardiovascular-risk patients with T2D now receive both a GLP-1 receptor agonist and an SGLT-2 inhibitor (empagliflozin or dapagliflozin), each with its own cardiovascular outcomes evidence. The DURATION-8 trial demonstrated that exenatide plus dapagliflozin produced additive glycemic lowering versus either agent alone. [9] Direct long-term CVOT data for dulaglutide plus an SGLT-2 inhibitor are not yet available from a single co-administration trial, but guidelines support using both in patients who have both cardiovascular and heart failure risk.

Patient Communication About Stroke Risk

The 24% relative reduction in non-fatal stroke is a clinically meaningful number to share with patients. For a 65-year-old T2D patient with one additional risk factor and no prior stroke, the absolute risk reduction may be smaller in percentage terms than in a secondary-prevention patient, but over 5 years it is real and reproducible across REWIND's broad subgroup analyses. Framing dulaglutide as a "weekly injection that lowers your stroke risk" often resonates more than framing it purely as a glucose-lowering agent.

Ongoing Research and Unanswered Questions

Several questions about dulaglutide's cardiovascular mechanism and optimal use remain open.

Dose-Response and Cardiovascular Outcomes

REWIND used only the 1.5 mg dose. Whether 3.0 mg, the maximum approved dose for T2D, would produce a larger cardiovascular benefit is unknown. Semaglutide's SELECT trial (N=17,604) tested 2.4 mg in patients without diabetes and found a 20% MACE reduction, raising the possibility that higher GLP-1 receptor agonism confers greater cardiovascular benefit. [10] A formal dose-comparison CVOT for dulaglutide does not currently exist.

Heart Failure Outcomes

REWIND was not powered to examine heart failure hospitalization as a primary endpoint. The cardiovascular death component (HR 0.91, not statistically significant) leaves open whether dulaglutide reduces fatal heart failure events. SGLT-2 inhibitors have more strong heart failure hospitalization data. Combining both classes may be the most comprehensive cardiovascular strategy, pending dedicated combination trial data.

Duration of Benefit After Discontinuation

No long-term extension data exist to describe what happens to cardiovascular event rates after dulaglutide discontinuation. Given that weight regain after GLP-1 cessation is well-documented (STEP-1 extension showed approximately 11.6% weight regain within one year of stopping semaglutide 2.4 mg) [11], it is reasonable to hypothesize that cardiovascular protection may attenuate after stopping, but direct data for dulaglutide are absent.

Clinical Bottom Line

Dr. Hertzel Gerstein, REWIND's principal investigator, stated in the original Lancet publication: "The cardiovascular benefit of dulaglutide was consistent regardless of whether participants had or did not have prior cardiovascular disease at baseline, suggesting that dulaglutide may be appropriate for the broad range of people with type 2 diabetes." [2]

That framing reflects how the evidence is being incorporated into practice. Dulaglutide is no longer simply a glucose-lowering agent with a favorable injection schedule. The 5.4-year REWIND dataset positions it as a drug with a documented, statistically significant, and guideline-endorsed cardiovascular risk reduction effect, most pronounced for stroke, applicable to primary and secondary prevention alike, and compatible with renal impairment.

For a patient with T2D at elevated cardiovascular risk who has not yet achieved adequate glycemic control on metformin, the 2024 ADA Standards of Care recommend adding a GLP-1 receptor agonist with proven cardiovascular benefit as the preferred next agent, independent of baseline HbA1c. [5] Dulaglutide 1.5 mg once weekly, titrated from 0.75 mg over 4 weeks, meets that standard and carries an FDA indication to confirm it.